Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Rapid antigen test for SARS-CoV-2 shows lower sensitivity

In a new study, researchers assessed a rapid antigen (Ag) test for SARS-CoV-2.

2 Feb 2022

Safety and immunogenicity of high-dose quadrivalent influenza vaccine and mRNA-1273 vaccine booster in older adults

A new study has determined the safety and immunogenicity after concomitant administration of QIV-HD and a third dose of the mRNA-1273 vaccine among older adults in the USA

2 Feb 2022

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

Scientists studied the ability of T cells to react with the Omicron spike.

2 Feb 2022

Quantitative framework to investigate the dynamic mechanism of host immune response confronting SARS-CoV-2 infection

The authors highlight that they have created a quantitative framework that allows the dynamic mechanism of the immune response to SARS-CoV-2 to be properly investigated.

2 Feb 2022

Assessing an intranasal lentiviral booster against COVID-19 variants

A new study explores the possibility of vaccination via nasal route utilizing a lentiviral vaccination vector (LV) to be administered as a booster dose against COVID-19.

2 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

Study uncovers a class of microbial enzymes that drive ulcerative colitis

Ulcerative colitis, a subtype of inflammatory bowel disease, is a chronic ailment of the colon affecting nearly one million individuals in the United States. It is thought to be linked to disruptions in the gut microbiome - the bacteria and other microbes that live inside us - but no existing treatments actually target these microorganisms.

2 Feb 2022

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants.

2 Feb 2022

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

New research posted to the medRxiv* preprint server finds patients with immune-mediated inflammatory diseases undergoing anti-TNF therapy had the greatest reduction of antibody levels three months after vaccination. In addition, they had weaker neutralization responses towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

1 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

Researchers analyze neutralizing antibodies against the SARS-CoV-2 VOCs with the sera of vaccinated individuals infected with the Omicron variant.

1 Feb 2022

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Study finds that high-dose convalescent plasma does not improve outcomes for severe COVID-19

A randomized controlled trial assesses the efficacy and safety of high-dose convalescent plasma in the treatment of severe COVID-19.

1 Feb 2022

New machine-learning model could speed up the process of developing new medicines

Antibodies, small proteins produced by the immune system, can attach to specific parts of a virus to neutralize it.

1 Feb 2022

High levels of neutralizing antibodies against Omicron after BNT162b2 booster vaccination

Researchers analyze the neutralizing antibody levels against SARS-CoV-2 VOCs in individuals after receiving their second and third doses.

1 Feb 2022

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

In a new study, researchers analyzed the effect of vaccine booster doses against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

In a new study, a team of researchers assessed the neutralizing activity of XAV-19, a glyco-humanized polyclonal antibody derived from hyperimmunized animal hosts, against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Impact of using AI to generate primers for detection of SARS-CoV-2 Omicron variant

In a new study, researchers designed artificial intelligence (AI)-based primers for the SARS-CoV-2 Omicron variant.

1 Feb 2022

Antibody News and Research

Further Reading

Rapid antigen test for SARS-CoV-2 shows lower sensitivity

Safety and immunogenicity of high-dose quadrivalent influenza vaccine and mRNA-1273 vaccine booster in older adults

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

Quantitative framework to investigate the dynamic mechanism of host immune response confronting SARS-CoV-2 infection

Assessing an intranasal lentiviral booster against COVID-19 variants

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Study uncovers a class of microbial enzymes that drive ulcerative colitis

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

Developing post-vaccination SARS-CoV-2 standard reference sera

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Study finds that high-dose convalescent plasma does not improve outcomes for severe COVID-19

New machine-learning model could speed up the process of developing new medicines

High levels of neutralizing antibodies against Omicron after BNT162b2 booster vaccination

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

Impact of using AI to generate primers for detection of SARS-CoV-2 Omicron variant

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo